All In Biotech

Drug Trial Radar · NCT00806026

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 731 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

731

Actual

Start

Dec 2008

Primary completion

May 2011

Study completion May 2011

Sponsor

Sponsor type
Industry
First posted
Dec 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.

Conditions

  • Idiopathic Restless Legs Syndrome

Interventions

  • placebo and pregabalinDrug

    following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.

  • pramipexolDrug

    following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

  • pramipexolDrug

    following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

  • PregabalinDrug

    pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

  • pramipexolDrug

    pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

  • pramipexolDrug

    pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Restless Legs Syndrome (RLS) Symptom SeverityTime frame: Baseline
  2. Change From Baseline in the RLS Symptom Severity at Week 12Time frame: Baseline, Week 12
  3. Percentage of Participants Responding to Treatment at Week 12Time frame: Week 12
  4. Percentage of Participants With AugmentationTime frame: Baseline up to Week 52

Locations

110 sites in 9 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Jasper, Alabama

  • Pfizer Investigational Site

    Tuscaloosa, Alabama

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Northridge, California

  • Pfizer Investigational Site

    Redondo Beach, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Santa Monica, California

  • Pfizer Investigational Site

    Torrance, California

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Boca Raton, Florida

  • Pfizer Investigational Site

    Hallandale, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    South Miami, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Overland Park, Kansas

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Baton Rouge, Louisiana

  • Pfizer Investigational Site

    Chevy Chase, Maryland

  • Pfizer Investigational Site

    Newton, Massachusetts

  • Pfizer Investigational Site

    Southfield, Michigan

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    Princeton, New Jersey

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Salisbury, North Carolina

  • Pfizer Investigational Site

    Salisbury, North Carolina

  • Pfizer Investigational Site

    Winston-Salem, North Carolina

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Columbus, Ohio

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma

  • Pfizer Investigational Site

    Lafayette Hill, Pennsylvania

  • Pfizer Investigational Site

    Austin, Texas

  • Pfizer Investigational Site

    Dallas, Texas

  • Pfizer Investigational Site

    Houston, Texas

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.